Taken together, these studies suggest that xenogeneic vaccination with hCSPG-4 in canine patients following surgical removal of melanoma tumors can enhance survival time by possibly driving an anti-tumor CSPG-4-specific response [35,36,37]. Here, CSPG4 is linked to melanoma.